skip to Main Content

Successful IPO of bm|t portfolio company inflaRx at NASDAQ

  • 2017

InflaRx, the bio­phar­ma­ceu­ti­cal com­pany devel­op­ing new ther­a­peu­tics in the ter­mi­nal com­ple­ment space, yes­ter­day announced the pric­ing of its ini­tial pub­lic offer­ing of 6,667,000 com­mon shares at an ini­tial pub­lic offer­ing price of $15.00 per com­mon share, for total gross pro­ceeds of approx­i­mately $100 mil­lion. In addi­tion, InflaRx has granted the under­writ­ers a 30-day option to pur­chase up to an addi­tional 1,000,050 com­mon shares at the pub­lic offer­ing price, less under­writ­ing dis­counts and com­mis­sions. All of the com­mon shares are being offered by InflaRx.

InflaRx GmbH

The shares started trad­ing on the NASDAQ Global Select Mar­ket on Novem­ber 8, 2017 under the ticker sym­bol “IFRX.”

J.P. Mor­gan, Leerink Part­ners and BMO Cap­i­tal Mar­kets acted as joint book-run­ning man­agers for the offering.

bm|t has been an investor in inflaRx from day one and is extremely proud have sup­ported yet another suc­cess story from Thuringia.

About InflaRx: InflaRx is a clin­i­cal-stage bio­phar­ma­ceu­ti­cal com­pany focused on apply­ing its pro­pri­etary anti-C5a tech­nol­ogy to dis­cover and develop first-in-class, potent and spe­cific inhibitors of C5a.

Con­tacts:

InflaRx GmbH
Prof. Dr. Niels C. Riede­mann — CEO
Email: info[at]inflarx.de
Tel: +49–3641-508180

MC Ser­vices AG
Dr. Clau­dia Gutjahr-Loeser
Email: inflarx[at]mc-services.eu
Tel: +49–89-210 2280

Back To Top
×Close search
Search